Crossed from claiming to demonstrating: management marks its own before/after line with repeated, recent proof
The model's full reasoning — Q3 2018 call → NOWe need to determine if management conveys a recent crossing from claiming to demonstrating something, with before/after contrast, repeated real events, and payoff mostly ahead. Let's analyze the transcript. Key topics: SurVeil DCB with Abbott, TRANSCEND trial, BTK/AV fistula programs, Embolitech thrombectomy, whole product solutions (Telemark microcatheter, .014/.018 balloons), IVD products. Look for management's own before/after contrast. For example, Gary says: "we are pleased to report strong operating performance and meaningful advances in our strategic objectives." But that's general. Specific potential crossings: The company has been developing products and now has regulatory clearances and commercial agreements. For instance, Telemark microcatheter received FDA clearance in Q2 fiscal 2018, and now "Early clinician feedback in cases treating patients continues to be overwhelmingly positive." That's a recent clearance and early use, but is it repeated? They mention "cases" plural, but it's early. Also they are still seeking partners. Not a clear before/after. Another: "We are also encouraged by our clinical regulatory achievements combined with ongoing top-line performance and operational progress." Not specific. The Embolitech acquisition: they acquired technology and are working on prototypes. That's early, not demonstrated. The SurVeil agreement with Abbott: they signed agreement, recognized revenue, but that's a deal, not a capability demonstrated. The IVD launch of MatrixGuard Diluent: "we recently launched" - that's a product launch, but is it repeated? It's a launch, not yet proven in market. The key phrase: "we are on track to become a leading and enduring medical device innovator" - future. Look for management drawing a line: "As many of you will recall, in late February we announced an agreement with Abbott... As a remainder, SurVeil is built on a next generation technology..." That's not a before/after. Maybe the whole product solutions: they have received clearances for .014 and .018 balloons, and now they are undergoing clinical evaluation by interested parties. That's still early.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| CNXC | Concentrix Corporation | Q1 2022 | 2022-03-30 | B |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
DXCM · Q4 2023 → YESThe question is about whether management conveys that the company has recently crossed from claiming something to demonstrating it. YES The transcript shows management drawing a clear before/after contrast on the Malaysia manufacturing facility: previously they relied on established US facilities, but mid-year they opened a new site and are now ramping production with yields matching the US ones—real, repeated activity rather than a single event or plan. This is framed as 2023 being transformational, with the new capability already contributing to results and positioned for further scaling ahead. The primary-care expansion also fits as a demonstrated shift from long-term investment to immediate results (70% of new scripts), but the manufacturing crossing is the clearest match to the criteria.
LC · Q4 2021 → YESThe question is about whether management conveys that the company has recently crossed from claiming something to demonstrating it. YES The transcript shows management drawing a clear before/after line: Scott Sanborn describes closing 2021 in the strongest position after executing a strategy laid out in February, creating America's first digital marketplace bank; Tom Casey states the radical transformation over the last year is now complete as promised, contrasting it with 2019 4Q revenue and net income levels to highlight the fundamental change. The after-side is real and repeated—record revenue, doubled economics, NII recurring stream, multiple quarters of strong performance—backed by actual bank operations and deliveries.
KTB · Q3 2021 → YESThe question is about whether management conveys that the company has recently crossed from claiming something to demonstrating it. YES Management draws its own before/after line in Scott Baxter’s opening remarks: “we are doing things with both the Wrangler and Lee brands that we have simply never done before,” directly contrasting past practice with the current reality of new marketing campaigns (Lee launched October, Wrangler September). The after-side is 1) real and recent (Q3 results show 50 % growth in U.S. outdoor and 60 % growth in work wear versus 2019 baselines) and 2) repeated across multiple categories and brands, confirming the capability is now operating rather than a one-off event.